Estrogen plus progestin and risk of benign proliferative breast disease.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Thomas E RohanD L Page

Abstract

Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74% increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95% confidence in...Continue Reading

References

Aug 5, 1992·Journal of the National Cancer Institute·N F BoydH L Han
Jan 1, 1985·Breast Cancer Research and Treatment·D Y Wang, I S Fentiman
Oct 15, 1984·International Journal of Cancer. Journal International Du Cancer·G S BerkowitzC White
May 21, 1999·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·T E Rohan, A B Miller
Jul 9, 1999·The Journal of Pathology·S R Lakhani
Aug 3, 2000·International Journal of Epidemiology·C FriedenreichD Page
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Aug 6, 2002·Journal of Mammary Gland Biology and Neoplasia·Sandra Z HaslamL J Hofseth
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Rowan T ChlebowskiUNKNOWN WHI Investigators
Oct 25, 2003·Annals of Epidemiology·Jennifer HaysJacques E Rossouw
Apr 15, 2004·JAMA : the Journal of the American Medical Association·Garnet L AndersonUNKNOWN Women's Health Initiative Steering Committee
May 24, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Carlo CampagnoliFranco Berrino
Jul 22, 2005·The New England Journal of Medicine·Lynn C HartmannDaniel W Visscher
Jul 22, 2005·The New England Journal of Medicine·Richard J Santen, Robert Mansel
Sep 20, 2005·Breast Cancer Research : BCR·Giske UrsinAnna H Wu
Sep 22, 2005·Journal of the National Cancer Institute·Anne McTiernanUNKNOWN Women's Health Initiative Mammogram Density Study Investigators
Jan 20, 2006·The New England Journal of Medicine·James D Yager, Nancy E Davidson
Nov 23, 2006·The Journal of Steroid Biochemistry and Molecular Biology·J Russo, Irma H Russo
Jan 19, 2007·The New England Journal of Medicine·Norman F BoydMartin J Yaffe
Feb 27, 2008·Archives of Internal Medicine·Rowan T ChlebowskiUNKNOWN Women's Health Initiative Investigators
Apr 10, 2008·Journal of the National Cancer Institute·Thomas E RohanDavid L Page

❮ Previous
Next ❯

Citations

Apr 13, 2010·Archives of Gynecology and Obstetrics·Adolf E Schindler
Nov 11, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tehillah S MenesDiana L Miglioretti
Sep 15, 2010·Fitoterapia·May Fern Toh, Joanna E Burdette
Oct 27, 2009·Journal de gynécologie, obstétrique et biologie de la reproduction·V LavouéJ Levêque
Jul 2, 2016·Expert Review of Anticancer Therapy·Ludivine DionVincent Lavoué
Jun 29, 2017·Histopathology·Ellen G EastJulie M Jorns
Apr 12, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zhong-Chao WangLi-Qun Ren
Sep 27, 2018·Breast Cancer Research and Treatment·Timothy M BarrowHyang-Min Byun
Apr 24, 2014·Cancer Research·Chelsea CatsburgThomas E Rohan
Mar 19, 2021·Climacteric : the Journal of the International Menopause Society·C Rueda BeltzA Bastidas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.